Sugi Predict

Sugi Predict / Compounds / SCHEMBL14968624

SCHEMBL14968624

SCHEMBL14968624

CC(=O)CCCCCCN1C(=O)C=CC1=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 7/20 0.70
▸ PTGS2 P35354 7/20 0.70
▸ MGLL Q99685 7/20 0.65
▸ FAAH O00519 5/20 0.65
▸ MAPK1 P28482 2/20 0.65
▸ HSP90AA1 P07900 1/20 0.65
▸ TLR9 Q9NR96 1/20 0.65
▸ ALDH1A1 P00352 1/20 0.65
▸ LMNA P02545 1/20 0.65
▸ TP53 P04637 1/20 0.65
▸ MAPT P10636 1/20 0.65
▸ PKM P14618 1/20 0.65
▸ HPGD P15428 1/20 0.65
▸ XBP1 P17861 1/20 0.65
▸ HTT P42858 1/20 0.65
▸ RECQL P46063 1/20 0.65
▸ RAB9A P51151 1/20 0.65
▸ SMN1; SMN2 Q16637 1/20 0.65
▸ NPSR1 Q6W5P4 1/20 0.65
▸ GPR35 Q9HC97 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22237613 1.00 PTGS1 (0.70) PTGS1PTGS2MGLLFAAHMAPK1
SCHEMBL10173306 1.00 PTGS1 (0.70) PTGS1PTGS2MGLLFAAHMAPK1
SCHEMBL24637632 1.00 PTGS1 (0.70) PTGS1PTGS2MGLLFAAHMAPK1
SCHEMBL14524212 0.98 PTGS1 (0.67) PTGS1PTGS2MGLLFAAHMAPK1
SCHEMBL10014802 0.92 MGLL (0.60) PTGS1PTGS2MGLLFAAHMAPK1
SCHEMBL19201659 0.88 PTGS1 (0.56) PTGS1PTGS2MGLLFAAHMAPK1
SCHEMBL18515827 0.88 PTGS1 (0.56) PTGS1PTGS2MGLLFAAHMAPK1
SCHEMBL15354307 0.84 PTGS1 (0.55) PTGS1PTGS2MGLLFAAHMAPK1
Acetic Acid SCHEMBL27987918 0.84 PTGS1 (0.69) PTGS1PTGS2MGLLFAAHMAPK1
SCHEMBL2734915 0.84 MGLL (0.52) PTGS1PTGS2MGLLFAAHMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3327027-B9 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER (US) 2021-07-07 — — EP disclosed
EP-3327027-B1 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER (US) 2021-01-06 — — EP disclosed
EP-3325497-B1 QUINSTATIN COMPOUNDS UNIV ARIZONA STATE (US) 2020-09-02 — — EP disclosed
US-10435435-B2 Quinstatin compounds THE ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2019-10-08 — — US disclosed
EP-3327027-A1 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF Pfizer Inc (US) 2018-05-30 — — EP disclosed
EP-2780039-B9 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER (US) 2018-04-18 — — EP disclosed
EP-2780039-B1 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER (US) 2017-11-29 — — EP disclosed
WO-2017019489-A1 QUINSTATIN COMPOUNDS PETTIT GEORGE ROBERT (US) 2017-02-02 — — WO disclosed
US-20170014526-A1 ANTI-NOTCH3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES PFIZER INC. (US) 2017-01-19 — — US disclosed
US-9433687-B2 Anti-Notch3 antibodies and antibody-drug conjugates PFIZER INC. (US) 2016-09-06 — — US disclosed
US-9249186-B2 Cytotoxic peptides and antibody drug conjugates thereof PFIZER INC. (US) 2016-02-02 — — US disclosed
US-20150307551-A1 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER INC. 2015-10-29 — — US disclosed
US-20150266917-A1 OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEOSIDE HAVING GUANIDINE BRIDGE OSAKA UNIVERSITY (JP) 2015-09-24 — — US disclosed
US-9138486-B2 Cytotoxic peptides and antibody drug conjugates thereof PFIZER INC. (US) 2015-09-22 — — US disclosed
US-20140363452-A1 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER INC. 2014-12-11 — — US disclosed
US-8828401-B2 Cytotoxic peptides and antibody drug conjugates thereof PFIZER INC. (US) 2014-09-09 — — US disclosed
WO-2014072897-A1 ANTI-NOTCH3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES PFIZER INC. (US) 2014-05-15 — — WO disclosed
US-20130129753-A1 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER INC. (US) 2013-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307551-A1 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF NGLY1, CD47, CD81 PTGS1 4781/4885PTGS2 4845/4885MGLL 4717/4885
US-20150266917-A1 OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEOSIDE HAVING GUANIDINE BRIDGE NSUN2, RNGTT, RNASEH1 PTGS1 2676/4885PTGS2 3247/4885MGLL 4488/4885
US-20140363452-A1 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF NGLY1, CD47, CD81 PTGS1 4781/4885PTGS2 4845/4885MGLL 4717/4885
US-10435435-B2 Quinstatin compounds QTRT1, COQ8A, QPCT PTGS1 2437/4885PTGS2 2829/4885MGLL 1412/4885
US-20170014526-A1 ANTI-NOTCH3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES NOTCH3, NOTCH4, NOTCH2 PTGS1 4383/4885PTGS2 4371/4885MGLL 4173/4885
US-20130129753-A1 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF NGLY1, CD47, CD81 PTGS1 4781/4885PTGS2 4845/4885MGLL 4717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.